

Elihu Estey

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2868019/elihu-estey-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163 papers	15,302 citations	44 h-index	123 g-index
176 ext. papers	18,137 ext. citations	5 avg, IF	6.56 L-index

#	Paper	IF	Citations
163	Intensive chemotherapy for acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
162	Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function.. <i>Cell Stem Cell</i> , 2022 ,	18	2
161	Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing.. <i>Leukemia Research</i> , 2022 , 115, 106822	2.7	
160	More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels. <i>Leukemia and Lymphoma</i> , 2021 , 1-4	1.9	
159	Loss of Lamin B1 in Myeloid Neoplasms with 5q Deletion Causes Myeloid-Biased Hematopoiesis and Pelger-Huet Nuclear Anomaly. <i>Blood</i> , 2021 , 138, 502-502	2.2	
158	Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of "Positive" Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 - 2015. <i>Blood</i> , 2021 , 138, 4040-4040	2.2	
157	Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 1-10	7.3	1
156	Comparative analysis of infectious complications with outpatient inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. <i>Leukemia and Lymphoma</i> , 2021 , 1-10	1.9	0
155	The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2021 ,	4.5	3
154	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1226-1233	1.9	7
153	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. <i>Haematologica</i> , 2021 , 106, 2114-2120	6.6	3
152	Are phase III trials still important for FDA drug approval?. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1287-1288	1.9	1
151	Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML). <i>Leukemia and Lymphoma</i> , 2021 , 62, 1532-1535	1.9	1
150	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2108-2117	4.4	1
149	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. <i>Blood</i> , 2021 ,	2.2	14
148	New treatments for acute myeloid leukemia: how much has changed?. <i>Leukemia</i> , 2021 , 35, 45-46	10.7	4
147	Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2021 , 62, 234-238	1.9	2

146	Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. <i>Leukemia Research</i> , 2020 , 89, 106298	2.7	9
145	Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. <i>Blood Reviews</i> , 2020 , 44, 100679	11.1	12
144	Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 9-10	2.2	
143	Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 12-13	2.2	
142	Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 12-13	2.2	0
141	Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?. <i>Leukemia</i> , 2020 , 34, 671-681	10.7	32
140	Need for routine examination of left ventricular ejection fraction in patients with AML. <i>Leukemia</i> , 2020 , 34, 1169-1171	10.7	1
139	Truth or consequences: under-reporting of post-accrual changes in clinical trial design. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2034-2035	1.9	
138	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020 , 4, 3239-3245	7.8	6
137	Acute myeloid leukemia: 2021 update on risk-stratification and management. <i>American Journal of Hematology</i> , 2020 , 95, 1368-1398	7.1	25
136	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Leukemia</i> , 2020 , 34, 635-639	10.7	6
135	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood Advances</i> , 2020 , 4, 611-616	7.8	10
134	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e633-e635	2	
133	More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 421-432	7.1	18
132	Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification. <i>JAMA Oncology</i> , 2019 , 5, 1062-1064	13.4	8
131	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019 , 133, 1630-1643	2.2	219
130	Chromosomal Abnormalities and Prognosis in -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2632-2642	2.2	40
129	Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. <i>Cancer</i> , 2019 , 125, 3121-3130	6.4	5

128	Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT). <i>Blood</i> , 2019 , 134, 4585-4585	2.2	1
127	Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 1364-1364	2.2	3
126	Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow. <i>Blood</i> , 2019 , 134, 2729-2729	2.2	1
125	Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms. <i>Blood</i> , 2019 , 134, 3824-3824	2.2	2
124	Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019 , 134, 260-260	2.2	2
123	Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)?. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7031-7031	2.2	4
122	Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia. <i>Blood</i> , 2019 , 134, 4674-4674	2.2	
121	Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. <i>Blood</i> , 2019 , 134, 291-291	2.2	
120	'Looking beyond survival to define therapeutic value in acute myeloid leukemia'. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1107-1109	1.9	1
119	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. <i>Leukemia</i> , 2019 , 33, 554-558	10.7	6
118	Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. <i>Leukemia</i> , 2019 , 33, 371-378	10.7	6
117	A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1023-1029	1.9	4
116	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1615-1620	4.7	20
115	Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Haematologica</i> , 2018 , 103, e106-e109	6.6	18
114	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. <i>Leukemia</i> , 2018 , 32, 2352-2362	10.7	21
113	Time to repeat and replace response criteria for acute myeloid leukemia?. <i>Blood Reviews</i> , 2018 , 32, 416-425	2.5	33
112	Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development. <i>Current Medical Research and Opinion</i> , 2018 , 34, 2031-2039	2.5	14
111	Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). <i>Journal of Drug Assessment</i> , 2018 , 7, 51-53	1.5	11

110	E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML. <i>Blood</i> , 2018 , 132, 1513-1513	2.2	2
109	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. <i>Blood</i> , 2018 , 132, 3978-3978	2.2	
108	Allogeneic Transplantation for Acute Myelogenous Leukemia in CR1. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 205-206	4.7	1
107	Acute myeloid leukemia: 2019 update on risk-stratification and management. <i>American Journal of Hematology</i> , 2018 , 93, 1267-1291	7.1	171
106	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 889-903	21.7	145
105	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. <i>Blood Reviews</i> , 2017 , 31, 185-192	11.1	42
104	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 424-447	2.2	2764
103	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. <i>Blood</i> , 2017 , 129, 1275-1283	2.2	144
102	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017 , 3, 1675-1682	13.4	78
101	Emerging treatments in acute myeloid leukemia: current standards and unmet challenges. <i>Clinical Advances in Hematology and Oncology</i> , 2017 , 15, 632-642	0.6	5
100	Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 324-328	4.2	7
99	Acute myeloid leukemia: 2016 Update on risk-stratification and management. <i>American Journal of Hematology</i> , 2016 , 91, 824-46	7.1	43
98	Acute myeloid leukaemia. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16010	51.1	159
97	Variability in management of hematologic malignancy patients with venous thromboembolism and chemotherapy-induced thrombocytopenia. <i>Thrombosis Research</i> , 2016 , 141, 104-5	8.2	12
96	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 329-36	2.2	270
95	Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. <i>Blood</i> , 2016 , 128, 1613-1613	2.2	2
94	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016 , 128, 216-216	2.2	16
93	Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 4050-4050	2.2	34

92	Rates of CR with and without Measurable Residual Disease after Induction Treatment with "7+3" or Azacitidine/Decitabine for Newly-Diagnosed AML. <i>Blood</i> , 2016 , 128, 2792-2792	2.2	
91	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1205-7	1.9	1
90	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e97-8	6.6	8
89	Why Is Progress in Acute Myeloid Leukemia So Slow?. <i>Seminars in Hematology</i> , 2015 , 52, 243-8	4	15
88	Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1157-64	2.2	86
87	Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1258-64	2.2	163
86	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e254-6	6.6	3
85	Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis. <i>JAMA Oncology</i> , 2015 , 1, 1120-7	13.4	33
84	Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 782-4	1.9	3
83	Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia. <i>Blood</i> , 2015 , 125, 2461-6	2.2	59
82	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. <i>Haematologica</i> , 2015 , 100, e409-11	6.6	9
81	Reply to D. Przepiorka et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3676-7	2.2	10
80	Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. <i>Haematologica</i> , 2015 , 100, 927-34	6.6	74
79	Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 546-51	4.7	19
78	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 2569-2569	2.2	1
77	A multicenter, open-label phase 2a study of ibrutinib with or without cytarabine in patients with acute myeloid leukemia (PCYC-1131).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS7096-TPS7096	2.2	1
76	Oncology Providers Ability to Prognosticate Patient Outcomes: An Analysis of the Survey on Provider Assessment of Risk (SPAR) Study. <i>Blood</i> , 2015 , 126, 5635-5635	2.2	
75	Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. <i>Blood</i> , 2015 , 126, 3776-3776	2.2	

74	Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015 , 126, 1339-1339	2.2	
73	An Automated System for Parsing and Risk Classifying Karyotype Nomenclature for Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 2602-2602	2.2	1
72	Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials. <i>Blood</i> , 2015 , 126, 688-688	2.2	
71	Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 549-55	4.7	38
70	Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3249-56	2.2	273
69	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology</i> , 2014 , 15, 986-96	21.7	410
68	A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 395-400.e1	2	5
67	Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. <i>Leukemia Research</i> , 2014 , 38, 258-62	2.7	5
66	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 21-33	3.1	29
65	Acute myeloid leukemia: 2014 update on risk-stratification and management. <i>American Journal of Hematology</i> , 2014 , 89, 1063-81	7.1	104
64	Primacy of resistance rather than toxicity in determining outcome of therapy for AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14 Suppl, S56-8	2	4
63	Management of persistent AML at day 14. <i>Best Practice and Research in Clinical Haematology</i> , 2014 , 27, 235-40	4.2	4
62	The past and future of CD33 as therapeutic target in acute myeloid leukemia. <i>Blood Reviews</i> , 2014 , 28, 143-53	11.1	107
61	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). <i>Leukemia Research Reports</i> , 2013 , 2, 26-8	0.6	2
60	Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3883-8	2.2	35
59	Are immunoconjugates approaching "standard of care" in AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2013 , 26, 261-8	4.2	
58	Acute myeloid leukemia: 2013 update on risk-stratification and management. <i>American Journal of Hematology</i> , 2013 , 88, 318-27	7.1	214
57	The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia. <i>Blood</i> , 2013 , 122, 293-4	2.2	3

56	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. <i>Blood</i> , 2013 , 122, 1813-21	2.2	264
55	Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. <i>Frontiers in Bioscience - Landmark</i> , 2013 , 18, 1311-34	2.8	46
54	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013 , 122, 356-356	2.2	8
53	Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic. <i>Blood</i> , 2013 , 122, 3924-3924	2.2	5
52	Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG. <i>Blood</i> , 2013 , 122, 3925-3925	2.2	4
51	Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study. <i>Blood</i> , 2013 , 122, 3936-3936	2.2	2
50	Personalized Approach To Treatment of Acute Myeloid Leukemia Using a High-Throughput Chemosensitivity Assay. <i>Blood</i> , 2013 , 122, 483-483	2.2	2
49	Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML. <i>Blood</i> , 2013 , 122, 5002-5002		1
48	Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation. <i>Blood</i> , 2013 , 122, 61-61	2.2	19
47	Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7021-7021	2.2	4
46	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 571-7	0.6	27
45	Phase 2 Study Of Early Discharge and Outpatient Management Of Adult Patients Following Intensive Induction Chemotherapy For MDS and Non-APL AML. <i>Blood</i> , 2013 , 122, 2932-2932	2.2	
44	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2013 , 122, 64-64	2.2	1
43	Mcl-1 Dependence Predicts Response To Vorinostat and Gemtuzumab Ozogamicin In Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 1305-1305	2.2	
42	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012 , 87, 89-99	7.1	118
41	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. <i>Blood</i> , 2012 , 119, 6198-208	2.2	217
40	Treatment of AML: resurrection for gemtuzumab ozogamicin?. <i>Lancet, The</i> , 2012 , 379, 1468-9	4.0	19
39	Intensity of conditioning for allogeneic haemopoietic cell transplantation. <i>Lancet Oncology, The</i> , 2012 , 13, 966-8	21.7	4

38	Gemtuzumab ozogamicin: time to resurrect?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3921-3	2.2	84
37	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 48-48	2.2	54
36	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 673-673	2.2	81
35	Acute Myeloid Leukemia (AML) 2012 , 1-36		
34	Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of Acute Myeloid Leukemia, Not Otherwise Specified in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2012 , 120, 540-540	2.2	
33	Cyclosporine Modulation of Multidrug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study. <i>Blood</i> , 2012 , 120, 4343-4343	2.2	
32	What is the optimal induction strategy for older patients?. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 515-22	4.2	1
31	The times they are a-changin'. <i>Blood</i> , 2011 , 117, 1774-5	2.2	
30	Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. <i>Blood</i> , 2011 , 118, 1490-4	2.2	86
29	Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1190-7	2.2	270
28	Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4417-23	2.2	230
27	Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1766-71	2.2	145
26	High cytogenetic or molecular genetic risk acute myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 474-80	3.1	11
25	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. <i>Blood</i> , 2010 , 116, 2420-8	2.2	62
24	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010 , 115, 453-74	2.2	2483
23	Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. <i>Journal of Clinical Oncology</i> , 2009 , 27, 504-10	2.2	306
22	Using short-term response information to facilitate adaptive randomization for survival clinical trials. <i>Statistics in Medicine</i> , 2009 , 28, 1680-9	2.3	41
21	AML in older patients: are we making progress?. <i>Best Practice and Research in Clinical Haematology</i> , 2009 , 22, 529-36	4.2	26

20	Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. <i>Blood</i> , 2009 , 113, 28-36	2.2	162
19	New drugs in acute myeloid leukemia. <i>Seminars in Oncology</i> , 2008 , 35, 439-48	5.5	14
18	Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 1263-5	6.6	35
17	Relapse and death during first remission in acute myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 633-4	6.6	24
16	Accounting for patient heterogeneity in phase II clinical trials. <i>Statistics in Medicine</i> , 2008 , 27, 2802-15	2.3	32
15	Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.. <i>Blood</i> , 2008 , 112, 3253-3253	2.2	4
14	Response in acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 113-7	0.6	4
13	Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). <i>Blood</i> , 2007 , 109, 1395-400	2.2	209
12	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. <i>Cancer</i> , 2006 , 106, 1090-8	6.4	478
11	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <i>Blood</i> , 2006 , 107, 3469-73	2.2	317
10	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. <i>Cancer</i> , 2005 , 104, 1442-52	6.4	364
9	New designs for phase 2 clinical trials. <i>Blood</i> , 2003 , 102, 442-8	2.2	96
8	Use of arsenic trioxide (As ₂ O ₃) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. <i>Cancer</i> , 2003 , 97, 2218-24	6.4	106
7	Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4642-9	2.2	2107
6	Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1722-7	2.2	73
5	Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. <i>Blood</i> , 2002 , 99, 4222-4	2.2	156
4	Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. <i>Blood</i> , 2002 , 99, 4343-9	2.2	130
3	Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. <i>Blood</i> , 2000 , 95, 72-77	2.2	82

2	Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work. <i>Blood</i> , 1997 , 90, 4719-4724	2.2	70
1	New Designs for Clinical Trials: Acute Myeloid Leukemia as an Example	419-428	